← Back
Data updated: Jul 17, 2026
Stallergenes, SAS
Biotech Pharmaceuticals
Stallergenes, SAS is a biotechnology company with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
Stallergenes, SAS's Key Drugs
Stallergenes, SAS's core commercial portfolio centers on Oralair — its most strategically important drugs approved in the last 15 years.
Stallergenes, SAS's Recent FDA Approvals
New NDA/BLA approvals for Stallergenes, SAS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
Stallergenes, SAS's Therapeutic Areas
Disease areas where Stallergenes, SAS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
Stallergenes, SAS Pipeline Snapshot
Active clinical trials for Stallergenes, SAS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Oralair leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-03-31
- Latest
- 2014-03-31
- Applications
- 1